According to Zacks, “VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company’s lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. “
Separately, Robert W. Baird assumed coverage on VistaGen Therapeutics in a research note on Sunday, October 17th. They issued a buy rating and a $9.00 target price on the stock.
VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Wednesday, November 10th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). VistaGen Therapeutics had a negative return on equity of 36.41% and a negative net margin of 2,183.17%. The business had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $0.33 million. During the same quarter in the previous year, the business earned ($0.05) EPS. As a group, equities research analysts forecast that VistaGen Therapeutics will post -0.27 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of VTGN. New York State Common Retirement Fund bought a new position in shares of VistaGen Therapeutics during the 2nd quarter worth $516,000. Rhumbline Advisers bought a new position in shares of VistaGen Therapeutics during the 2nd quarter worth $449,000. Ameritas Investment Partners Inc. bought a new position in shares of VistaGen Therapeutics during the 2nd quarter worth $47,000. HighTower Advisors LLC grew its position in shares of VistaGen Therapeutics by 7.9% during the 2nd quarter. HighTower Advisors LLC now owns 136,078 shares of the company’s stock worth $429,000 after buying an additional 10,000 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new position in shares of VistaGen Therapeutics during the 2nd quarter worth $92,000. 65.77% of the stock is currently owned by institutional investors and hedge funds.
About VistaGen Therapeutics
VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company’s portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder (SAD); PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD); and AV-101 which the company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy.
Further Reading: Fibonacci Channel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.